CR20230253A - Glucoformas de fab ricas en manosa - Google Patents

Glucoformas de fab ricas en manosa

Info

Publication number
CR20230253A
CR20230253A CR20230253A CR20230253A CR20230253A CR 20230253 A CR20230253 A CR 20230253A CR 20230253 A CR20230253 A CR 20230253A CR 20230253 A CR20230253 A CR 20230253A CR 20230253 A CR20230253 A CR 20230253A
Authority
CR
Costa Rica
Prior art keywords
high mannose
fab
glycoforms
fab high
mannose glycoforms
Prior art date
Application number
CR20230253A
Other languages
English (en)
Inventor
Klaus Joeris
Wolfgang Richter
Carsten Hofmann
Britta Schmidt
Neslihan Oezden
Wilma Lau
Roland Staack
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20230253A publication Critical patent/CR20230253A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a patrones de glucosilación en la porción Fab de un anticuerpo monoclonal y procedimientos para la regulación durante el cultivo de un microorganismo que expresa un anticuerpo monoclonal con contenido regulado de glucoformas de Fab ricas en manosa.
CR20230253A 2020-11-16 2021-11-04 Glucoformas de fab ricas en manosa CR20230253A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207804 2020-11-16
PCT/EP2021/080692 WO2022101088A1 (en) 2020-11-16 2021-11-04 Fab high mannose glycoforms

Publications (1)

Publication Number Publication Date
CR20230253A true CR20230253A (es) 2023-07-26

Family

ID=73452078

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230253A CR20230253A (es) 2020-11-16 2021-11-04 Glucoformas de fab ricas en manosa

Country Status (13)

Country Link
US (1) US20240002483A1 (es)
EP (1) EP4244248A1 (es)
JP (1) JP2023549809A (es)
KR (1) KR20230109674A (es)
CN (1) CN116615231A (es)
AU (1) AU2021376837A1 (es)
CA (1) CA3200954A1 (es)
CL (1) CL2023001371A1 (es)
CR (1) CR20230253A (es)
IL (1) IL302740A (es)
MX (1) MX2023005581A (es)
PE (1) PE20231556A1 (es)
WO (1) WO2022101088A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240043501A1 (en) * 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
WO2024246085A1 (en) * 2023-05-31 2024-12-05 F. Hoffmann-La Roche Ag Therapeutic use of bispecific anti-abeta/tfr antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CA2632828C (en) * 2005-12-12 2012-07-10 F. Hoffmann-La Roche Ag Antibodies against amyloid beta with glycosylation in the variable region
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
BR112016011027A2 (pt) 2013-12-20 2017-12-05 Genentech Inc método de produção de um anticorpo, anticorpos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, método de tratamento de asma e método de tratamento de um distúrbio
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO

Also Published As

Publication number Publication date
CA3200954A1 (en) 2022-05-19
AU2021376837A9 (en) 2025-04-10
AU2021376837A1 (en) 2023-06-15
WO2022101088A1 (en) 2022-05-19
CN116615231A (zh) 2023-08-18
US20240002483A1 (en) 2024-01-04
JP2023549809A (ja) 2023-11-29
PE20231556A1 (es) 2023-10-03
EP4244248A1 (en) 2023-09-20
IL302740A (en) 2023-07-01
CL2023001371A1 (es) 2023-12-01
MX2023005581A (es) 2023-05-29
KR20230109674A (ko) 2023-07-20

Similar Documents

Publication Publication Date Title
MX2023005581A (es) Glucoformas de fab ricas en manosa.
ZA202203653B (en) Anti-transferrin receptor antibodies with tailored affinity
PH12021552910A1 (en) Variant dihydrodipicolinate reductase polypeptide and method of producing l-threonine using the same
PH12021552901A1 (en) L-threonine export protein variant and method for production of l-threonine using same
NZ785401A (en) Anti-ms4a4a antibodies and methods of use thereof
MX2023003086A (es) Métodos para tratar el mieloma múltiple.
WO2021203030A3 (en) Methods of use of anti-trem2 antibodies
WO2010076400A8 (fr) Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome intraoculaire primitif
ZA202208337B (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
WO2020218951A3 (ru) Моноклональное антитело, которое специфически связывается с gitr
MX2024010949A (es) Variantes de proteina de eflujo de l-treonina y metodo de produccion de l-treonina utilizando la misma
MX2024010950A (es) Variantes de proteina de eflujo de l-treonina y metodo de produccion de l-treonina utilizando la misma
PH12022552741A1 (en) Anti-ox40 antibody and uses thereof
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
ZA202305429B (en) Antibody for tetanus toxin and use thereof
MX2022005238A (es) Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida.
MX2025013338A (es) Composiciones de epcoritamab altamente purificadas
PH12021552900A1 (en) Modified polypeptide of meso-diaminopimelate dehydrogenase and method for producing l-threonine using the same
GEP20247609B (en) Ethod of producing botulinum toxin
MY195400A (en) Microorganism Having Enhanced L-Threonine Producing Ability and Method for Producing Threonine using the same
MX2021012765A (es) Metodos para tratar el cancer renal con un anticuerpo anti-psma/cd3.
ZA202106551B (en) Anti-bag2 antibody and methods of treating cancer
WO2024054678A3 (en) Antibodies against fentanyl and analogs and methods of use thereof
MX2024008725A (es) Material aerosolizable.
EP3998280A4 (en) HYBRIDOME AND METHOD FOR PRODUCTION, MONOCLONAL ANTIBODY AND METHOD FOR PRODUCTION